Contrave (naltrexone HCl and bupropion HCl). Extended-Release Tablets, 8mg/90 mg, 120-count bottles, Rx only, Distributed by Orexigen therapeutics, Inc., La Jolla, CA 92037, NDC 51267-890-99
Published November 14, 2018 · Recall initiated: October 5, 2018
Summary
FDA records drug Class III recall D-0219-2019, published November 14, 2018 and initiated October 5, 2018. Recalling firm: Orexigen Therapeutics, Inc.; Status: Terminated; Reported quantity: 18,895 bottles; Lot: Lot #: ZYCY, Exp. 04/11/2021. Class III means the product is not likely to cause adverse health consequences.
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Container packaging defect.
What to do
Voluntary: Firm initiated · Letter
Get an email if CONTRAVE has another recall
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Brand
- CONTRAVE
- Manufacturer
- Orexigen Therapeutics, Inc.
- Distributor
- Within the United States
- UPC
- 0351267890997
- Lot
- Lot #: ZYCY, Exp. 04/11/2021
- Risk classification
- Class III
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDAOrtho-Novum 7/7/7 (norethindrone/ethinyl/estradiol) Tablets, 0.5 mg/0.035 mg, 0.75 mg/0.035 mg, 1 mg/0.035,November 14, 2018
- FDAAlcohol Free Foaming Hand Sanitizer (benzalkonium chloride), 0.13%, 1 L (33.8 fl. oz.) cartridge packaged in 8November 14, 2018
- FDAOrtho-Novum 1/35 (norethindrone/ethinyl estradiol) Tablets, 1 mg/0.035 mg, 28-Day Regimen per pouch (NDCNovember 14, 2018
- FDAMetoprolol Tartrate Injection, USP, 5 mg/ 5 mL (1 mg/mL), 5 mL per sterile single use glass vial, Rx Only,November 14, 2018
- FDA0.9% Sodium Chloride Injection, USP Rx Only a) 250 mL NDC 0409-7983-02; b) 150 mL NDC 0409-7983-61; c) 50 mLNovember 14, 2018
- FDAContrave (naltrexone HCl and bupropion HCl) Extended-Release Tablets, 8 mg/90 mg, 120-count bottle, Rx only,August 22, 2018
Questions about this recall
Was Contrave (naltrexone HCl and bupropion HCl). Extended-Release Tablets, 8mg/90 mg, 120-count bottles, Rx only, Distributed by Orexigen therapeutics, Inc., La Jolla, CA 92037, NDC 51267-890-99 recalled?
Yes. FDA published recall D-0219-2019 on November 14, 2018. Reported hazard: Container packaging defect.
What should I do if I have this product?
Voluntary: Firm initiated · Letter
How do I know if my unit is part of the recall?
Compare your product details with the notice. Brand: CONTRAVE. UPC: 0351267890997.